Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioPorto A/S receives intention to grant for NGAL exclusion patent in Europe

Friday, 21 Feb 2014 02:50am EST 

BioPorto A/S:Says the European Patent Office has published intention to grant BioPorto’s patent no. EP2064553 regarding exclusion of acute kidney injury.Says the patent is part of BioPorto’s IP rights in the NGAL area and is complementary to the NGAL cutoff patent. 

Related Company News

Company Quote

0.1 +5.65%
19 Dec 2014